<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11785512</article-id><article-id pub-id-type="doi">10.7759/cureus.76727</article-id><article-categories><subj-group subj-group-type="heading"><subject>Emergency Medicine</subject></subj-group><subj-group><subject>Gastroenterology</subject></subj-group><subj-group><subject>Internal Medicine</subject></subj-group></article-categories><title-group><article-title>Hypomagnesemia Causing Convulsions in a Patient Taking a Proton Pump Inhibitor: A Case Report</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Takanobu</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ohashi</surname><given-names>Ryogo</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Konishi</surname><given-names>Katsuya</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Teuon</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ichibayashi</surname><given-names>Ryo</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Division of Emergency Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, JPN </aff><author-notes><corresp id="cor1">
Ryo Ichibayashi <email>ryou.ichibayashi@med.toho-u.ac.jp</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>1</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>1</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>e76727</elocation-id><history><date date-type="accepted"><day>1</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Sato et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Sato et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/331325-hypomagnesemia-causing-convulsions-in-a-patient-taking-a-proton-pump-inhibitor-a-case-report">This article is available from https://www.cureus.com/articles/331325-hypomagnesemia-causing-convulsions-in-a-patient-taking-a-proton-pump-inhibitor-a-case-report</self-uri><abstract><p>Long-term administration of proton pump inhibitors (PPIs) has been increasingly recognized to cause hypomagnesemia due to impaired magnesium absorption in both the small and large intestines. Hypomagnesemia can lead to various electrolyte imbalances, including hypokalemia, hypocalcemia, and, less commonly, hyponatremia and hypophosphatemia. Measuring serum magnesium levels is essential for identifying the underlying cause in patients receiving PPIs with unexplained electrolyte abnormalities.</p><p>Currently, no standardized treatment exists for PPI-induced hypomagnesemia beyond discontinuing PPI therapy and administering magnesium supplements. The main preventive strategies in managing acid-related diseases may be a case-by-case endoscopic evaluation and early discontinuation of PPIs.</p><p>This report describes a case of multiple electrolyte abnormalities, including hypomagnesemia, associated with PPI use. It highlights that serum magnesium levels may require several weeks to return to baseline following PPI discontinuation. In outpatient management, repeated serum magnesium measurements over several months are necessary rather than relying on a single assessment post-discontinuation. Furthermore, among the affected electrolytes, magnesium normalization is the most delayed, underscoring the importance of monitoring serum magnesium levels to assess treatment efficacy in cases of complex electrolyte disturbances.</p></abstract><kwd-group kwd-group-type="author"><kwd>electrolyte abnormalities</kwd><kwd>esomeprazole</kwd><kwd>gastric ulcers</kwd><kwd>hypomagnesemia</kwd><kwd>proton pump inhibitor</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Proton pump inhibitors (PPIs) are drugs widely used to treat diseases involving gastric acid, such as gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease. PPIs have shown superior efficacy in treating acid-related disorders to histamine H<sub>2</sub> receptor antagonists (H<sub>2</sub>RAs) and have replaced H<sub>2</sub>RAs. The package inserts for PPIs recommend that they be administered for several weeks. Still, in clinical practice, they are often administered for long periods, resulting in side effects associated with long-term use [<xref rid="REF1" ref-type="bibr">1</xref>].</p><p>A typical example is impaired absorption of trace elements. Hypomagnesemia (low magnesium levels) affects the nervous, muscular, cardiovascular, and metabolic systems, causing various symptoms. The mechanism by which long-term PPI use reduces intestinal magnesium absorption and causes hypomagnesemia is gradually being elucidated. This side effect has been reported as an essential PPI-related problem [<xref rid="REF2" ref-type="bibr">2</xref>-<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>This report describes a case of symptomatic hypomagnesemia, with accompanying hypokalemia (low potassium levels) and hypocalcemia (low calcium levels), caused by the long-term administration of esomeprazole to treat gastric ulcers.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 64-year-old man had been treated for prostate cancer, hypertension, and gastric ulcer. He was taking amlodipine, olmesartan, atenolol, tadalafil, naftopidil, esomeprazole, and Miya-BM&#x000ae; (<italic>Clostridium butyricum</italic> MIYAIRI 588 strain; Miyarisan Pharmaceutical Co.&#x000a0;Ltd., Tokyo, Japan). He had no history of smoking, and his drinking history was occasional. He had nausea and loss of appetite four days before his visit. As his symptoms continued, he visited a nearby clinic and was prescribed an antiemetic. His symptoms did not improve, and he became dizzy and unable to move, so he called an ambulance. His vital signs at the time of his visit showed that he was drowsy, but he was conscious and had a Glasgow Coma Scale score of 15, blood pressure of 141/100 mmHg, respirations of 29/min, pulse of 111/min, and peripheral oxygen saturation (SpO<sub>2</sub>) of 98%. During the examination, he had generalized tonic convulsions. The convulsions immediately stopped after intravenous injection of 20 mg of diazepam. An ECG showed sinus rhythm, but a prolonged QTc of 516 ms was observed (Figure <xref rid="FIG1" ref-type="fig">1</xref>). No abnormalities were found on the head CT&#x000a0;(Figure <xref rid="FIG2" ref-type="fig">2</xref>). The patient was admitted to the hospital on the same day to be examined for anorexia and seizures. The blood test results at the time of admission are shown in Table <xref rid="TAB1" ref-type="table">1</xref>.</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>ECG at the time of admission</title><p>QTc was prolonged to 516 ms.</p></caption><graphic xlink:href="cureus-0017-00000076727-i01" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Head CT</title><p>No abnormal findings.</p></caption><graphic xlink:href="cureus-0017-00000076727-i02" position="float"/></fig><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Laboratory results upon admission</title><p>CRP: C-reactive protein, TP: total protein, Alb: albumin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, &#x003b3;-GTP: &#x003b3;-glutamyl transpeptidase, CK: creatinine kinase, BUN: blood urea nitrogen, eGFR: estimated glomerular filtration, WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, HbA1c: hemoglobin A1c, Plt: platelet, TSH: thyroid stimulating hormone, FT3: free thyroid 3, FT4: free thyroid 4, PTH: parathyroid hormone, BE: base excess, SG: specific gravity,&#x000a0;pCO<sub>2</sub>: partial pressure of carbon dioxide, HCO<sub>3</sub>&#x0207b;: bicarbonate, UN: urea nitrogen</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Test</td><td rowspan="1" colspan="1">Result</td><td rowspan="1" colspan="1">Unit</td><td rowspan="1" colspan="1">Reference value</td></tr><tr><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">0.26</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">&#x0003c;0.3</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">TP</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">g/dL</td><td rowspan="1" colspan="1">6.7-8.3</td></tr><tr><td rowspan="1" colspan="1">Alb</td><td rowspan="1" colspan="1">5.0</td><td rowspan="1" colspan="1">g/dL</td><td rowspan="1" colspan="1">3.8-5.2</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">AST</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">IU/L</td><td rowspan="1" colspan="1">10-40</td></tr><tr><td rowspan="1" colspan="1">ALT</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">IU/L</td><td rowspan="1" colspan="1">5-45</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">LDH</td><td rowspan="1" colspan="1">323</td><td rowspan="1" colspan="1">U/L</td><td rowspan="1" colspan="1">124-222</td></tr><tr><td rowspan="1" colspan="1">&#x003b3;-GTP</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">IU/L</td><td rowspan="1" colspan="1">&#x0003c;30</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CK</td><td rowspan="1" colspan="1">1944</td><td rowspan="1" colspan="1">IU/L</td><td rowspan="1" colspan="1">60-270</td></tr><tr><td rowspan="1" colspan="1">BUN</td><td rowspan="1" colspan="1">27.5</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">8.0-20.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Creatinine</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">0.47-0.79</td></tr><tr><td rowspan="1" colspan="1">eGFR</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">mL/min/1.73m<sup>2</sup>
</td><td rowspan="1" colspan="1">&#x0003e;60</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sodium</td><td rowspan="1" colspan="1">145</td><td rowspan="1" colspan="1">mEq/L</td><td rowspan="1" colspan="1">137-147</td></tr><tr><td rowspan="1" colspan="1">Potassium</td><td rowspan="1" colspan="1">3.1</td><td rowspan="1" colspan="1">mEq/L</td><td rowspan="1" colspan="1">3.5-5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Chlorine</td><td rowspan="1" colspan="1">95</td><td rowspan="1" colspan="1">mEq/L</td><td rowspan="1" colspan="1">98-108</td></tr><tr><td rowspan="1" colspan="1">Calcium</td><td rowspan="1" colspan="1">8.3</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">8.4-10.4</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Phosphorus</td><td rowspan="1" colspan="1">2.6</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">2.5-4.5</td></tr><tr><td rowspan="1" colspan="1">Magnesium</td><td rowspan="1" colspan="1">&#x0003c;0.3</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">1.9-2.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Glucose</td><td rowspan="1" colspan="1">224</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">70-109</td></tr><tr><td rowspan="1" colspan="1">HbA1c</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">&#x0ff05;</td><td rowspan="1" colspan="1">4.7&#x0ff5e;6.2</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">WBC</td><td rowspan="1" colspan="1">19960</td><td rowspan="1" colspan="1">/&#x003bc;L</td><td rowspan="1" colspan="1">3300-9000</td></tr><tr><td rowspan="1" colspan="1">Hb</td><td rowspan="1" colspan="1">14.1</td><td rowspan="1" colspan="1">g/dL</td><td rowspan="1" colspan="1">13.5-17.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Plt</td><td rowspan="1" colspan="1">36.5</td><td rowspan="1" colspan="1">10<sup>4</sup>/&#x003bc;L</td><td rowspan="1" colspan="1">14-34</td></tr><tr><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">1.62</td><td rowspan="1" colspan="1">&#x003bc;IU/mL</td><td rowspan="1" colspan="1">0.35-4.94</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">FT3</td><td rowspan="1" colspan="1">2.91</td><td rowspan="1" colspan="1">pg/mL</td><td rowspan="1" colspan="1">1.68-3.67</td></tr><tr><td rowspan="1" colspan="1">FT4</td><td rowspan="1" colspan="1">1.37</td><td rowspan="1" colspan="1">ng/dL</td><td rowspan="1" colspan="1">0.70-1.48</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PTH-intact</td><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">pg/mL</td><td rowspan="1" colspan="1">10-65</td></tr><tr><td rowspan="1" colspan="1">Calcitonin</td><td rowspan="1" colspan="1">1.30</td><td rowspan="1" colspan="1">pg/mL</td><td rowspan="1" colspan="1">&#x0003c;5.15</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Venous blood gas</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">7.566</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">7.330-7.410</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">pCO<sub>2</sub>
</td><td rowspan="1" colspan="1">24.2</td><td rowspan="1" colspan="1">mmHg</td><td rowspan="1" colspan="1">43-53</td></tr><tr><td rowspan="1" colspan="1">HCO<sub>3</sub>&#x0207b;</td><td rowspan="1" colspan="1">21.5</td><td rowspan="1" colspan="1">mmol/L</td><td rowspan="1" colspan="1">24-28</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">BE</td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">mmol/L</td><td rowspan="1" colspan="1">0-4</td></tr><tr><td rowspan="1" colspan="1">Lactate</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Urinalysis</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">7.5</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">5.0&#x0ff5e;8.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">SG</td><td rowspan="1" colspan="1">1.025</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1.010&#x0ff5e;1.025</td></tr><tr><td rowspan="1" colspan="1">UN</td><td rowspan="1" colspan="1">308</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Creatinine</td><td rowspan="1" colspan="1">315.98</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Sodium</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">mEq/L</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Potassium</td><td rowspan="1" colspan="1">71.7</td><td rowspan="1" colspan="1">mEq/L</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Magnesium</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">mg/dL</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">WBC</td><td rowspan="1" colspan="1">5-9</td><td rowspan="1" colspan="1">/HPF</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Bacteria</td><td rowspan="1" colspan="1">(1+)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">(-)</td></tr></tbody></table></table-wrap><p>Blood tests showed hypokalemia, hypocalcemia, and hypomagnesemia. Other findings included elevated creatinine kinase (CK) and white blood cell&#x000a0;(WBC) count. Although there was no elevation in C-reactive protein (CRP), bacteriuria and abdominal CT showed elevated perirenal fat tissue density on both sides, leading to a diagnosis of urinary tract infection. No abnormal findings were found on the MRI or EEG. Therefore, the cause of the convulsions, nausea, dizziness, and loss of appetite was diagnosed as severe hypomagnesemia. On the first day of hospitalization, 20 mEq of magnesium sulfate was administered intravenously in one shot, followed by continuous administration of 40 mEq of magnesium sulfate over 24 hours to correct the condition slowly. On the second day of hospitalization, serum magnesium had improved to 2.1 mg/dL, and symptoms had improved. Since the uncorrected fractional excretion of magnesium (FEMg) was 1%, it was determined to be an extrarenal loss. The cause of hypomagnesemia was suspected to be oral esomeprazole. On the fourth day of hospitalization, upper gastrointestinal endoscopy was performed, and no abnormal findings were found in the esophagus, stomach, or duodenum. Therefore, oral administration of esomeprazole was discontinued. Hypokalemia and hypocalcemia improved naturally without the need for special correction. On the fifth day of hospitalization, serum magnesium temporarily decreased to 1.7 mg/dL, and 20 mEq of magnesium sulfate was administered. After confirming the increase in CK associated with convulsions and the disappearance of symptoms, the patient was discharged on the seventh day of hospitalization. Seven days after discharge, the patient developed diarrhea, and serum magnesium decreased to 1.5 mg/dL, but no oral treatment was administered. Eighteen days after discharge, diarrhea improved, and serum magnesium was 1.9 mg/dL. No correction was performed thereafter, and serum magnesium was 1.8 mg/dL 28 days after discharge, maintaining typical values. The progress of blood electrolyte test results is shown in Table <xref rid="TAB2" ref-type="table">2</xref>.</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Electrolyte course of blood tests during hospitalization and after discharge</title><p>This table presents laboratory data and esomeprazole administration details from the day of hospitalization (Day 1) to the post-discharge follow-up (Day 35). Serum magnesium levels: Hypomagnesemia was prominent on Day 1, and gradual recovery was observed after discontinuing esomeprazole. Serum potassium concentration: Hypokalemia was observed initially, improving with treatment.</p><p>FEMg: Fractional excretion of magnesium</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="2" colspan="1">&#x000a0;</td><td colspan="5" rowspan="1">Hospitalization</td><td colspan="3" rowspan="1">After discharge</td><td rowspan="1" colspan="1">Reference value</td></tr><tr><td rowspan="1" colspan="1">Day 1</td><td rowspan="1" colspan="1">Day 2</td><td rowspan="1" colspan="1">Day 3</td><td rowspan="1" colspan="1">Day 5</td><td rowspan="1" colspan="1">Day 7</td><td rowspan="1" colspan="1">Day 14</td><td rowspan="1" colspan="1">Day 25</td><td rowspan="1" colspan="1">Day 35</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Esomeprazole</td><td rowspan="1" colspan="1">(+)</td><td rowspan="1" colspan="1">(+)</td><td rowspan="1" colspan="1">(+)</td><td rowspan="1" colspan="1">(&#x02212;)</td><td rowspan="1" colspan="1">(&#x02212;)</td><td rowspan="1" colspan="1">(&#x02212;)</td><td rowspan="1" colspan="1">(&#x02212;)</td><td rowspan="1" colspan="1">(&#x02212;)</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Magnesium sulfate administration (g)</td><td rowspan="1" colspan="1">7.38</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2.46</td><td rowspan="1" colspan="1">1.32</td><td rowspan="1" colspan="1">1.32</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">-</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Magnesium (mg/dL)</td><td rowspan="1" colspan="1">&#x0003c;0.3</td><td rowspan="1" colspan="1">2.1</td><td rowspan="1" colspan="1">1.9</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">1.9</td><td rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">1.9-2.5</td></tr><tr><td rowspan="1" colspan="1">Corrected calcium (mg/dL)</td><td rowspan="1" colspan="1">8.3</td><td rowspan="1" colspan="1">8.1</td><td rowspan="1" colspan="1">8.1</td><td rowspan="1" colspan="1">9.1</td><td rowspan="1" colspan="1">9.6</td><td rowspan="1" colspan="1">9.9</td><td rowspan="1" colspan="1">9.5</td><td rowspan="1" colspan="1">9.3</td><td rowspan="1" colspan="1">8.4-10.4</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sodium (mEq/L)</td><td rowspan="1" colspan="1">145</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">139</td><td rowspan="1" colspan="1">141</td><td rowspan="1" colspan="1">141</td><td rowspan="1" colspan="1">140</td><td rowspan="1" colspan="1">143</td><td rowspan="1" colspan="1">137-147</td></tr><tr><td rowspan="1" colspan="1">Potassium (mEq/L)</td><td rowspan="1" colspan="1">3.1</td><td rowspan="1" colspan="1">2.8</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3.8</td><td rowspan="1" colspan="1">4.2</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">4.2</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">3.5-5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Phosphorus (mg/dL)</td><td rowspan="1" colspan="1">2.6</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2.3</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">2.9</td><td rowspan="1" colspan="1">2.9</td><td rowspan="1" colspan="1">3.1</td><td rowspan="1" colspan="1">2.5-4.5</td></tr><tr><td rowspan="1" colspan="1">Creatinine</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">1.09</td><td rowspan="1" colspan="1">0.76</td><td rowspan="1" colspan="1">0.68</td><td rowspan="1" colspan="1">0.68</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">0.87</td><td rowspan="1" colspan="1">0.89</td><td rowspan="1" colspan="1">0.47-0.79</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">FEMg (%)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><p>The ECG showed an improvement in the QTc interval to 419 ms, and the patient ceased outpatient treatment (Figure <xref rid="FIG3" ref-type="fig">3</xref>). Based on the above history and findings, it was diagnosed that the oral administration of esomeprazole caused hypomagnesemia.</p><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>ECG after treatment</title><p>&#x000a0;The QTc interval improved to 419 ms.</p></caption><graphic xlink:href="cureus-0017-00000076727-i03" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Approximately 30% to 50% of daily magnesium intake is absorbed in the digestive tract. Notably, there is a negative correlation between intake and absorption efficiency - the higher the intake, the lower the absorption rate [<xref rid="REF3" ref-type="bibr">3</xref>]. Magnesium absorption in the intestinal tract occurs through two distinct pathways: the paracellular and transcellular pathways. In the distal jejunum and ileum of the small intestine, magnesium is primarily absorbed via the paracellular pathway. This process involves the diffusion of magnesium ions between epithelial cells through tight junctions, a mechanism regulated by cation-selective proteins such as claudin 2 (CLDN2), CLDN7, and CLDN12. In contrast, the transcellular pathway facilitates magnesium&#x000a0;absorption in the large intestine. This pathway relies on specific channels and transport proteins. On the luminal side, transient receptor potential M6 (TRPM6) and TRPM7 channels enable magnesium&#x000a0;ions to enter the epithelial cells. Subsequently, cyclin M4 (CNNM4) on the basolateral side ensures the transport of magnesium&#x000a0;into the bloodstream, completing the absorption process. This integrated mechanism highlights these pathways' distinct yet complementary roles in maintaining magnesium homeostasis within the body [<xref rid="REF3" ref-type="bibr">3</xref>,<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>PPIs may increase intestinal pH, reducing the solubility of magnesium&#x000a0;and thereby decreasing its absorption efficiency. Additionally, PPIs are thought to increase transepithelial electrical resistance (TEER) and reduce paracellular permeability, further impairing magnesium&#x000a0;absorption in the small intestine [<xref rid="REF3" ref-type="bibr">3</xref>,<xref rid="REF4" ref-type="bibr">4</xref>]. Elevated intestinal pH due to PPIs may also affect TRPM6/7 channel activity in the large intestine, disrupting transcellular magnesium transport [<xref rid="REF3" ref-type="bibr">3</xref>,<xref rid="REF4" ref-type="bibr">4</xref>]. Moreover, PPI-induced reductions in gut microbiota diversity may hinder bacterial fermentation in the colon, preventing acidification and further compromising magnesium absorption [<xref rid="REF3" ref-type="bibr">3</xref>].</p><p>The time to onset of PPI-induced hypomagnesemia varies significantly among individuals, with a median onset of 5.5 years. However, reported onset times range widely from 14 days to 13 years, making it challenging to predict hypomagnesemia based on the duration of PPI use alone [<xref rid="REF5" ref-type="bibr">5</xref>]. In this case, the 12-year duration of PPI administration exceeds the median, highlighting the unpredictable nature of this adverse effect.</p><p>Currently, there is no established treatment for PPI-induced hypomagnesemia beyond discontinuing PPIs and administering magnesium supplementation [<xref rid="REF3" ref-type="bibr">3</xref>]. Serum magnesium levels guide dosage adjustments in patients with stable hemodynamics. If renal function is normal and serum magnesium levels are &#x0003c;1.0 mg/dL (0.8 mEq/L), 1-2 g of magnesium sulfate (8-16 mEq of magnesium) is administered over 30-60 minutes, followed by 4-8 g of magnesium sulfate (32-64 mEq of magnesium) infused slowly over 12-24 hours [<xref rid="REF6" ref-type="bibr">6</xref>]. Administration continues until serum magnesium levels reach &#x02265;1.0 mg/dL. If serum magnesium levels are &#x02265;1.0 mg/dL (0.8 mEq/L), 4-8 g of magnesium sulfate (32-64 mEq of magnesium) is administered slowly over 12-24 hours [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>In this case, serum magnesium levels were &#x0003c;0.3 mg/dL initially. As an outpatient, the patient received 2.46 g of magnesium sulfate over 60 minutes, which increased serum magnesium levels to 1.2 mg/dL. Upon hospitalization, 4.92 g of magnesium sulfate was administered continuously over 24 hours on the first day. On days 2, 5, and 7, and after discharge on day 14, 1.23-2.46 g of magnesium sulfate was administered repeatedly over 60 minutes to achieve a target serum magnesium level of &#x02265;1.9 mg/dL. As a result, serum magnesium levels normalized on the 25th day of hospitalization. The half-life of repeated oral administration of 10 mg of esomeprazole is approximately 1.16 hours, and its blood concentration is assumed to approach zero within 24 hours of discontinuation. However, despite discontinuing esomeprazole on the fourth day of hospitalization, it took approximately three weeks for serum magnesium levels to normalize. Since the patient could consume adequate food during hospitalization and had no other medications or factors contributing to hypomagnesemia, intestinal magnesium absorption may take several weeks to recover even after esomeprazole is eliminated from the body.</p><p>In a study comparing the time to relapse of hypomagnesemia after resuming PPIs - including omeprazole, esomeprazole, pantoprazole, lansoprazole, and rabeprazole - no significant difference was observed among these drugs. This finding suggests that switching between PPIs is not effective in preventing hypomagnesemia [<xref rid="REF5" ref-type="bibr">5</xref>]. Conversely, it remains controversial whether switching to a different antacid, such as an H<sub>2</sub>RAs, offers any benefit [<xref rid="REF5" ref-type="bibr">5</xref>]. It has been reported that prebiotics and probiotics might help prevent PPI-induced mineral deficiencies [<xref rid="REF7" ref-type="bibr">7</xref>]. However, in this case, a butyric acid preparation was already being used alongside PPIs before hospitalization, suggesting limited effectiveness in preventing electrolyte abnormalities. Given these observations, early discontinuation of PPIs combined with a case-by-case gastrointestinal endoscopy is currently considered the only reliable preventive strategy against PPI-induced hypomagnesemia. Hypomagnesemia can lead to hypokalemia, hypocalcemia, and, in rare cases, hypophosphatemia and hyponatremia [<xref rid="REF2" ref-type="bibr">2</xref>]. Therefore, measuring serum magnesium levels in long-term PPI therapy patients with hypokalemia, hypocalcemia, or other unexplained electrolyte imbalances is crucial.</p><p>Potassium&#x000a0;is transported into cells via the sodium-potassium adenosine triphosphatase (Na&#x0207a;-K&#x0207a;-ATPase) pump in the distal tubule and collecting duct of the kidney. It is then secreted into the tubular lumen through two potassium channels: renal outer medullary potassium (ROMK) and big potassium (BK) channels [<xref rid="REF8" ref-type="bibr">8</xref>]. Magnesium normally inhibits the ROMK channel. In cases of hypomagnesemia, this inhibition is lost, leading to persistent potassium secretion through the ROMK channel and subsequent hypokalemia. As a result, hypokalemia associated with hypomagnesemia is often resistant to potassium supplementation alone, and magnesium replacement is typically required to correct the imbalance [<xref rid="REF8" ref-type="bibr">8</xref>].</p><p>Additionally, hypomagnesemia can cause functional hypoparathyroidism [<xref rid="REF9" ref-type="bibr">9</xref>]. When serum magnesium levels decrease, the &#x003b1; subunit of the G protein (G&#x003b1; protein) is inhibited, leading to activation of the calcium-sensing receptor (CaSR) in the parathyroid gland and subsequent suppression of parathyroid hormone (PTH) secretion [<xref rid="REF10" ref-type="bibr">10</xref>]. Intravenous administration of magnesium has been shown to increase PTH secretion rapidly within minutes [<xref rid="REF10" ref-type="bibr">10</xref>]. In this case, PTH levels were measured on the second day of hospitalization, after magnesium had already been administered, which may explain the slightly elevated PTH level compared to baseline. Furthermore, magnesium acts as a cofactor for adenylate cyclase, and its deficiency can disrupt signal transduction at the parathyroid hormone 1 receptor (PTH1R), contributing to hypocalcemia [<xref rid="REF11" ref-type="bibr">11</xref>].</p><p>In this patient, serum potassium and calcium levels improved shortly after discontinuing PPI therapy and normalized by the fifth day of hospitalization. However, serum magnesium levels required longer to normalize, underscoring the prolonged recovery period for magnesium homeostasis after chronic PPI exposure. Indeed, it is essential to continue monitoring serum magnesium levels for several months following PPI discontinuation&#x000a0;as long-term electrolyte replacement may be necessary to replenish body stores fully [<xref rid="REF2" ref-type="bibr">2</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This case highlights convulsive symptoms resulting from severe hypomagnesemia induced by long-term oral administration of esomeprazole. The underlying mechanism of PPI-induced hypomagnesemia involves impaired magnesium absorption, alterations in intestinal flora, and subsequent electrolyte imbalances. These findings emphasize the importance of regular serum magnesium monitoring in patients undergoing long-term PPI therapy. Additionally, unnecessarily prolonged use of PPIs should be avoided to mitigate the risk of potentially severe electrolyte abnormalities and associated complications.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Ryo Ichibayashi, Takanobu Sato</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Ryo Ichibayashi, Ryogo Ohashi, Katsuya Konishi, Takanobu Sato, Teuon Cho</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Ryo Ichibayashi, Takanobu Sato</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Ryo Ichibayashi, Ryogo Ohashi, Katsuya Konishi, Takanobu Sato, Teuon Cho</p><p><bold>Supervision:</bold>&#x000a0; Ryo Ichibayashi</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Side effects of long-term proton pump inhibitor use: a review</article-title><source>Basic Clin Pharmacol Toxicol</source><person-group>
<name><surname>Haastrup</surname><given-names>PF</given-names></name>
<name><surname>Thompson</surname><given-names>W</given-names></name>
<name><surname>S&#x000f8;ndergaard</surname><given-names>J</given-names></name>
<name><surname>Jarb&#x000f8;l</surname><given-names>DE</given-names></name>
</person-group><fpage>114</fpage><lpage>121</lpage><volume>123</volume><year>2018</year><pub-id pub-id-type="pmid">29658189</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Multiple electrolyte disorders triggered by proton pump inhibitor-induced hypomagnesemia: case reports with a&#x000a0;mini-review of the literature</article-title><source>Clin Nephrol Case Stud</source><person-group>
<name><surname>Souza</surname><given-names>CC</given-names></name>
<name><surname>Rigueto</surname><given-names>LG</given-names></name>
<name><surname>Santiago</surname><given-names>HC</given-names></name>
<name><surname>Seguro</surname><given-names>AC</given-names></name>
<name><surname>Girardi</surname><given-names>AC</given-names></name>
<name><surname>Luchi</surname><given-names>WM</given-names></name>
</person-group><fpage>6</fpage><lpage>11</lpage><volume>12</volume><year>2024</year><pub-id pub-id-type="pmid">38222324</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Mechanisms of proton pump inhibitor-induced hypomagnesemia</article-title><source>Acta Physiol (Oxf)</source><person-group>
<name><surname>Gommers</surname><given-names>LM</given-names></name>
<name><surname>Hoenderop</surname><given-names>JG</given-names></name>
<name><surname>de Baaij</surname><given-names>JH</given-names></name>
</person-group><volume>235</volume><year>2022</year></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Intestinal absorption and factors influencing bioavailability of magnesium - an update</article-title><source>Curr Nutr Food Sci</source><person-group>
<name><surname>Schuchardt</surname><given-names>JP</given-names></name>
<name><surname>Hahn</surname><given-names>A</given-names></name>
</person-group><fpage>260</fpage><lpage>278</lpage><volume>13</volume><year>2017</year><pub-id pub-id-type="pmid">29123461</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Systematic review: hypomagnesaemia induced by proton pump inhibition</article-title><source>Aliment Pharmacol Ther</source><person-group>
<name><surname>Hess</surname><given-names>MW</given-names></name>
<name><surname>Hoenderop</surname><given-names>JG</given-names></name>
<name><surname>Bindels</surname><given-names>RJ</given-names></name>
<name><surname>Drenth</surname><given-names>JP</given-names></name>
</person-group><fpage>405</fpage><lpage>413</lpage><volume>36</volume><year>2012</year><pub-id pub-id-type="pmid">22762246</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Treatment of electrolyte disorders in adult patients in the intensive care unit</article-title><source>Am J Health Syst Pharm</source><person-group>
<name><surname>Kraft</surname><given-names>MD</given-names></name>
<name><surname>Btaiche</surname><given-names>IF</given-names></name>
<name><surname>Sacks</surname><given-names>GS</given-names></name>
<name><surname>Kudsk</surname><given-names>KA</given-names></name>
</person-group><fpage>1663</fpage><lpage>1682</lpage><volume>62</volume><year>2005</year><pub-id pub-id-type="pmid">16085929</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Is it useful to administer probiotics together with proton pump inhibitors in children with gastroesophageal reflux?</article-title><source>J Neurogastroenterol Motil</source><person-group>
<name><surname>Belei</surname><given-names>O</given-names></name>
<name><surname>Olariu</surname><given-names>L</given-names></name>
<name><surname>Dobrescu</surname><given-names>A</given-names></name>
<name><surname>Marcovici</surname><given-names>T</given-names></name>
<name><surname>Marginean</surname><given-names>O</given-names></name>
</person-group><fpage>51</fpage><lpage>57</lpage><volume>24</volume><year>2018</year><pub-id pub-id-type="pmid">29291607</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Mechanism of hypokalemia in magnesium deficiency</article-title><source>J Am Soc Nephrol</source><person-group>
<name><surname>Huang</surname><given-names>CL</given-names></name>
<name><surname>Kuo</surname><given-names>E</given-names></name>
</person-group><fpage>2649</fpage><lpage>2652</lpage><volume>18</volume><year>2007</year><pub-id pub-id-type="pmid">17804670</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits</article-title><source>J Biol Chem</source><person-group>
<name><surname>Quitterer</surname><given-names>U</given-names></name>
<name><surname>Hoffmann</surname><given-names>M</given-names></name>
<name><surname>Freichel</surname><given-names>M</given-names></name>
<name><surname>Lohse</surname><given-names>MJ</given-names></name>
</person-group><fpage>6763</fpage><lpage>6769</lpage><volume>276</volume><year>2001</year><pub-id pub-id-type="pmid">11102444</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Impaired release of parathyroid hormone in magnesium deficiency</article-title><source>J Clin Endocrinol Metab</source><person-group>
<name><surname>Anast</surname><given-names>CS</given-names></name>
<name><surname>Winnacker</surname><given-names>JL</given-names></name>
<name><surname>Forte</surname><given-names>LR</given-names></name>
<name><surname>Burns</surname><given-names>TW</given-names></name>
</person-group><fpage>707</fpage><lpage>717</lpage><volume>42</volume><year>1976</year><pub-id pub-id-type="pmid">177448</pub-id>
</element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency</article-title><source>Clin Endocrinol (Oxf)</source><person-group>
<name><surname>Rude</surname><given-names>RK</given-names></name>
<name><surname>Oldham</surname><given-names>SB</given-names></name>
<name><surname>Singer</surname><given-names>FR</given-names></name>
</person-group><fpage>209</fpage><lpage>224</lpage><volume>5</volume><year>1976</year><pub-id pub-id-type="pmid">182417</pub-id>
</element-citation></ref></ref-list></back></article>